LumiThera completes Diopsys acquisition
LumiThera Inc., which provides photobiomodulation treatment for ocular damage and disease, completed its acquisition of visual electrophysiology medical device manufacturer Diopsys Inc.
The acquisition will add diagnostic and monitoring capabilities to LumiThera’s existing treatment platform, the Valeda Light Delivery System, and comes before the potential release of LumiThera’s 13-month U.S. LIGHTSITE III trial data on age-related macular degeneration, LumiThera announced in a press release.
“The LIGHTSITE III trial mirrors FDA approval trials for wet AMD drugs in endpoints and duration, in measuring the progression of vision loss in intermediate dry AMD patients, and how Valeda treatments can improve vision and impact disease progression,” Clark E. Tedford, PhD, president and CEO of LumiThera, said in the release. “We have also seen increased adoption of Valeda's noninvasive treatment for patients in approved European and South American countries over the last 2 years. We are excited to expand the approved use to the U.S. and other global populations.”
Joe Fontanetta, president of Diopsys, added, “We are excited for the new combined entity and the potential to prevent vision loss. The theranostic company will provide the tools eye care professionals need to diagnose, treat and monitor patients, providing a solution for multiple ocular diseases with limited treatment options.”
The Valeda Light Delivery System has only been approved for commercial use in the EU.
Read more about